- Home
- FOLD
as 05-08-2025 4:00pm EST
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 2.9B | IPO Year: | 2007 |
| Target Price: | $16.22 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.20 - $12.65 | Next Earning Date: | 05-01-2025 |
| Revenue: | $543,141,000 | Revenue Growth: | 28.25% |
| Revenue Growth (this year): | 21.87% | Revenue Growth (next year): | 22.19% |
Stock Insider Trading Activity of Amicus Therapeutics Inc. (FOLD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Campbell Bradley L | FOLD | President and CEO | Feb 19 '25 | Sell | $10.00 | 400 | $4,000.00 | 1,150,657 |
Latest Amicus Therapeutics Inc. News
FOLD Breaking Stock News: Dive into FOLD Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
Simply Wall St.
5 days ago
Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations
Zacks
7 days ago
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
MT Newswires
7 days ago
UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating
Pharmaceutical Technology
8 days ago
Dimerix and Amicus to commercialise DMX-200 in US
MT Newswires
8 days ago
Amicus Therapeutics Turns to Non-GAAP Q1 Earnings, Revenue Rises; Shares Down
Zacks
8 days ago
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
Associated Press Finance
8 days ago
Amicus Therapeutics: Q1 Earnings Snapshot
Compare FOLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.